Home » Archives by category » Clinical Trial News
VectivBio begins phase 3 trial of apraglutide in short bowel syndrome

VectivBio begins phase 3 trial of apraglutide in short bowel syndrome

VectivBio has dosed the first patient in its phase 3 STARS clinical trial of its synthetic GLP-2 analog apraglutide in short bowel syndrome (SBS). The Swiss clinical-stage biotech company said that the STARS trial is the largest phase 3 trial to be ever held in short bowel syndrome with intestinal failure (SBS-IF). The late-stage trial […]

BirchBioMed reports positive results for keloid scars candidate FS2 in phase 2 trial

BirchBioMed has reported positive results from a phase 2 trial evaluating the use of topical FS2, the company’s antifibrotic platform therapy, in the treatment of keloid scars. The Canadian clinical-stage immunology company said that the double-blind study delivered statistically significant results compared to Mederma, a market leading scar cream and a vehicle (placebo cream) in […]

Continue reading …
Dr. Reddy’s Laboratories gets DCGI nod for phase 3 trial of Sputnik V vaccine

Dr. Reddy’s Laboratories has secured the go-ahead from the Drugs Control General of India (DCGI) to begin phase 3 clinical trial for the Russian Covid-19 vaccine Sputnik V in India. The Indian pharma company plans to hold the phase 3 study on 1500 volunteers as part of the randomized, double-blind, parallel-group, placebo-controlled study. G V […]

Continue reading …
Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V

Indian pharma company Dr. Reddy’s Laboratories announced that Sputnik V, a registered Covid-19 vaccine in Russia, has succeeded in a phase 2 trial in India by meeting the primary endpoint of safety. An independent data and safety monitoring board (DSMB) has recommended the Sputnik V Covid-19 vaccine to be advanced to a phase 3 trial […]

Continue reading …
OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo

OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]

Continue reading …
Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL

Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). BNZ-1 is an immuno-modulator drug candidate. It is a multi-cytokine inhibitor of three interleukins, that includes IL-2, IL-9, and IL-15. It is the lead asset from Bioniz Therapeutics’ platform of […]

Continue reading …
WCG acquires clinical trial solutions provider Trifecta Clinical

US-based clinical service company WCG has acquired Trifecta Clinical, a provider of technology-enabled clinical trial solutions for an undisclosed price. The acquisition includes Trifecta Clinical’s site communication platform InvestigatorSpace, virtual training programs, and also safety documentation services. WCG provides solutions for improving the quality and efficiency of clinical research. The acquisition of Trifecta will expand […]

Continue reading …
PRESECO clinical trial for Avigan : Appili begins dosing in phase 3 Covid-19 study

Appili Therapeutics said that it has dosed the first participant in the phase 3 PRESECO clinical trial for Avigan tablets (favipiravir) for the oral treatment of Covid-19. The Canadian infectious disease biopharma company Appili is involving PRA Health Sciences as a clinical research organization (CRO) for administering the Covid-19 clinical trial at 47 outpatient sites. […]

Continue reading …
NaQuinate : Haoma Medica completes human trial of osteoporosis candidate

Haoma Medica has wrapped up a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as an oral treatment for osteoporosis. The UK-based biotech company initiated the human trial of NaQuinate last year in healthy adults for assessing its single and multiple doses. The primary goal of the trial was to evaluate […]

Continue reading …
Antengene gets NMPA nod for eltanexor phase 1/2 clinical trial in myelodysplastic syndrome

Antengene has been given approval from China’s National Medical Products Administration (NMPA) for a phase 1/2 clinical trial of ATG-016 (eltanexor) in myelodysplastic syndrome (MDS). The Chinese biopharma company will enroll patients having intermediate and higher risk myelodysplastic syndrome as determined by the Revised International Prognostic Scoring System (IPSS-R) after the failure of hypomethylating agents […]

Continue reading …
Page 1 of 19123Next ›Last »